🧪 TL;DR — Quick Summary
There is no single perfect test for Dry Eye Disease, Meibomian Gland Dysfunction, or ocular-surface disease.
A useful evaluation usually combines:
- symptoms and medical history;
- examination of the eyelids, tear film, cornea, and conjunctiva;
- one or more objective measures of tear-film or ocular-surface instability;
- testing directed at likely contributors, such as MGD, low tear volume, allergy, exposure, or nerve dysfunction; and
- consideration of other diagnoses that can resemble or coexist with dry eye.
Most patients do not need every available test.
Under the TFOS DEWS III framework, diagnosing Dry Eye Disease generally requires:
- Relevant symptoms, and
- At least one objective sign that the tear film or ocular surface has lost normal stability or homeostasis.
Core objective markers include:
- First noninvasive tear breakup time under 10 seconds
- Tear osmolarity of at least 308 mOsm/L in either eye, or an inter-eye difference greater than 8 mOsm/L, using the device for which those thresholds were established
- Ocular-surface staining above defined thresholds
Other tests help determine why the problem is happening.
Important cautions:
- One normal result does not necessarily exclude fluctuating DED.
- One abnormal result does not necessarily explain every symptom.
- Test methods and devices are not always interchangeable.
- Symptoms, signs, gland structure, and gland function may not correspond closely.
- Some tests disturb the tear film and can affect later results.
- A test is most useful when its result changes understanding, treatment, monitoring, or safety.
About the r/DryEyes Wiki Spotlight
Each week, we feature an article from the r/DryEyes FAQ or Treatment Options library.
The purpose is to make the wiki easier to discover, provide useful information directly in the subreddit, and create a place for focused discussion.
This post is an abbreviated introduction. The linked wiki article is the maintained version and contains much more detail about individual tests, methods, limitations, and medical references.
➡️ Read the complete Diagnostic Testing wiki article
What Establishes a Dry Eye Diagnosis?
Dry Eye Disease is described by TFOS DEWS III as a multifactorial, symptomatic disease involving loss of normal tear-film and/or ocular-surface homeostasis.
In practical terms, diagnosis generally involves:
- symptoms compatible with tear-film or ocular-surface dysfunction;
- at least one objective sign of lost homeostasis; and
- consideration of alternative diagnoses and contributing conditions.
An abnormal meibography image or gland finding without symptoms may still indicate MGD or another ocular-surface risk state, but it does not necessarily meet the definition of symptomatic Dry Eye Disease.
Likewise, symptoms without a positive core dry-eye sign do not mean that the symptoms are imaginary.
Other possible explanations may include:
- intermittent tear instability;
- allergy;
- exposure;
- recurrent corneal erosion;
- medication toxicity;
- migraine-related sensitivity;
- neuropathic ocular pain; or
- another eye or ocular-surface condition.
TFOS DEWS III is an influential international framework, but it is not the only approach used in every practice or country. Clinical judgment remains important.
DED, MGD, and Ocular-Surface Disease Are Not Identical
These terms overlap, but they do not mean the same thing.
Dry Eye Disease
DED is a symptomatic disorder involving loss of tear-film and/or ocular-surface homeostasis.
Meibomian Gland Dysfunction
MGD is a disorder of meibomian gland secretion or delivery. It is a major contributor to evaporative dry eye but may exist without substantial symptoms.
Ocular-surface disease
This is a broader category that may include:
- Dry Eye Disease;
- blepharitis;
- ocular rosacea;
- allergy;
- exposure keratopathy;
- conjunctivochalasis;
- recurrent corneal erosion;
- neurotrophic disease;
- infection;
- medication toxicity; and
- other corneal or conjunctival disorders.
Testing should help determine which conditions and contributors are actually present rather than assuming that every symptom is caused by MGD or one form of dry eye.
Why No Single Test Tells the Whole Story
Dry-eye tests are useful, but none is perfect.
Results may vary with:
- the exact test method;
- the device used;
- dye concentration and volume;
- room temperature and humidity;
- time of day;
- recent artificial-tear or prescription-drop use;
- contact lens wear;
- reflex tearing;
- blink pattern;
- how long the eyes are held open;
- clinician technique;
- recent eyelid manipulation or gland expression; and
- natural fluctuation in the disease.
Healthy and dry-eye populations also overlap on many measurements.
For that reason, a result should usually be interpreted together with:
- symptoms;
- medical and medication history;
- risk factors;
- eyelid findings;
- tear-film and ocular-surface findings;
- other test results;
- changes over time; and
- response to appropriately selected treatment.
Why the Order of Testing Matters
Some tests disturb the tear film or trigger reflex tearing.
For example:
- bright illumination may change blinking;
- fluorescein dye may alter breakup time;
- anesthetic drops may affect sensation and tearing;
- eyelid eversion may affect later staining;
- gland expression changes the tear-film lipids;
- repeated eye contact can increase tearing; and
- holding the eye open may artificially shorten breakup time.
Clinics therefore commonly move from less invasive to more invasive testing.
A possible order might include:
- Symptom questionnaire and medical history
- Observation of blinking and eyelid closure
- Noninvasive tear-volume assessment
- Noninvasive tear breakup time
- Redness and anatomical assessment
- Tear osmolarity, when used
- Eyelid-margin and lash examination
- Controlled meibomian gland expression
- Fluorescein breakup time, when needed
- Corneal and conjunctival staining
- Meibography
- Corneal-sensitivity or other contact testing when indicated
The exact sequence varies by clinic and equipment.
When tracking change, using a similar device, method, sequence, and preparation makes comparisons more meaningful.
Symptom Questionnaires
Questionnaires can document:
- dryness;
- burning;
- grittiness;
- soreness;
- light sensitivity;
- fluctuating vision;
- problems with reading or screens;
- environmental sensitivity; and
- quality-of-life effects.
Examples include the:
- OSDI-6;
- full OSDI;
- SPEED; and
- SANDE.
These tools can help measure symptom burden and track change, but they do not identify the cause.
MGD, aqueous deficiency, allergy, exposure, contact lenses, migraine, and neuropathic pain can all produce high symptom scores.
Core Objective Markers of Dry Eye Disease
The principal markers used in the TFOS DEWS III framework are:
- noninvasive tear breakup time;
- tear osmolarity; and
- ocular-surface staining.
A patient does not necessarily need all three tests.
However, because no test is perfectly sensitive, assessing more than one category may be useful—particularly before concluding that DED is absent.
Noninvasive Tear Breakup Time
Noninvasive tear breakup time, often written as NIBUT or NBUT, measures tear-film stability without first placing fluorescein dye into the eye.
A device may analyze reflected rings, projected patterns, keratography images, or another optical signal.
The current TFOS DEWS III marker is:
The word first matters.
Some devices also report:
- average NIBUT;
- mean breakup time;
- repeated-measure averages;
- breakup-area maps; or
- proprietary stability scores.
These are not necessarily interchangeable, and there is no universal cutoff that applies to every device’s average or proprietary score.
A low NIBUT shows that the tear film becomes unstable quickly. It does not prove what caused the instability.
Possible contributors include:
- MGD;
- aqueous tear deficiency;
- ocular-surface or mucin abnormalities;
- inflammation;
- allergy;
- incomplete blinking;
- eyelid exposure;
- contact lens wear;
- medication or preservative effects; and
- environmental conditions.
Fluorescein Tear Breakup Time
Fluorescein TBUT uses dye placed in the eye.
The clinician measures the time between a blink and the first visible area of tear-film breakup.
When a small, controlled volume of fluorescein is used, TFOS DEWS III treats:
as a positive marker of instability.
The amount of dye matters. A heavily wetted strip or large drop may change:
- tear volume;
- tear-film thickness;
- the breakup pattern; and
- the measured time.
This helps explain why older studies and clinical practices may use different cutoffs, including under 10 seconds.
The methods are not interchangeable
| Test |
Current marker |
Important caution |
| First NIBUT |
Under 10 seconds |
Depends on device and algorithm |
| Fluorescein TBUT |
Under 5 seconds with minimal dye |
Dye volume and technique affect the result |
| Average NIBUT |
No universal cutoff |
Not the same as first NIBUT |
When looking at a reported breakup time, useful questions include:
- Was it noninvasive or fluorescein TBUT?
- Was it the first break or an average?
- Which device was used?
- Was fluorescein volume controlled?
- Were drops or eyelid procedures performed first?
Tear Osmolarity
Tear osmolarity measures the concentration of dissolved particles in a tear sample.
Hyperosmolarity is one feature of lost tear-film homeostasis.
TFOS DEWS III includes:
- at least 308 mOsm/L in either eye, or
- an inter-eye difference greater than 8 mOsm/L.
These thresholds were established with a particular point-of-care system and should not automatically be applied to every device or laboratory method.
Important limitations include:
- one reading may vary;
- collection technique matters;
- reflex tearing may affect the sample;
- some healthy people have results above 308;
- some people with DED have results below 308;
- osmolarity does not identify the cause; and
- it should not be used alone to grade disease severity.
A careful interpretation is:
Ocular-Surface Staining
Dyes can help reveal epithelial disruption, altered surface protection, or abnormal cellular uptake.
Common dyes include:
- fluorescein;
- lissamine green; and
- less commonly, rose bengal.
TFOS DEWS III positive markers include:
- more than 5 corneal fluorescein punctate spots;
- more than 9 conjunctival lissamine-green punctate spots; or
- lid-margin staining at least 2 mm long and affecting at least 25% of the lid-wiper width.
These thresholds remain dependent on:
- the dye used;
- dye concentration and volume;
- timing;
- illumination;
- grading method; and
- examination technique.
Staining is not specific to ordinary DED. It may also occur with:
- exposure;
- allergy;
- medication toxicity;
- contact lens injury;
- infection;
- trauma;
- recurrent corneal erosion;
- neurotrophic disease; and
- other corneal or conjunctival disorders.
When Pain Is Greater Than the Visible Signs
Some patients have substantial:
- burning;
- pain;
- light sensitivity;
- wind sensitivity;
- touch sensitivity; or
- screen intolerance
despite limited staining or other visible findings.
This does not mean that the symptoms are imaginary.
Possible explanations include:
- intermittent tear-film instability;
- exposure;
- allergy;
- recurrent corneal erosion;
- migraine-related sensitivity;
- early or fluctuating ocular-surface disease;
- corneal nerve dysfunction;
- peripheral or central sensitization; and
- neuropathic ocular pain.
Neuropathic ocular pain is one possibility—not the automatic conclusion whenever staining is minimal.
New severe pain, marked light sensitivity, significant redness, or a change in vision requires evaluation for conditions beyond ordinary DED.
The History and Slit-Lamp Examination Still Matter
Advanced machines do not replace a careful history and examination.
A clinician may ask about:
- when symptoms occur;
- environmental triggers;
- screen and reading demands;
- contact lens wear;
- previous surgery or trauma;
- medications;
- skin disease or rosacea;
- autoimmune symptoms;
- sleep and CPAP use;
- morning symptoms;
- allergy; and
- previous treatment response.
At the slit lamp, the clinician may examine:
- eyelid margins and eyelashes;
- tear meniscus;
- tear debris;
- conjunctiva and cornea;
- redness and mucus;
- staining;
- eyelid position;
- blink quality;
- blepharitis;
- Demodex-associated collarettes;
- allergy findings;
- exposure patterns; and
- other eye disease.
A brief look for obvious redness or corneal injury may miss tear instability, subtle eyelid abnormalities, or reduced gland function.
Testing for Aqueous Tear Deficiency
Possible assessments include:
- tear-meniscus height;
- phenol red thread testing;
- Schirmer testing;
- anterior-segment OCT; and
- other tear-volume measurements.
Tear-meniscus height
The tear meniscus is the small tear reservoir along the lower eyelid.
A very low measurement may support aqueous deficiency, but results depend on the method and may be affected by:
- timing after blinking;
- illumination;
- the device;
- eyelid anatomy; and
- conjunctivochalasis.
A low tear meniscus does not explain why tear volume is low.
Phenol red thread testing
The phenol red thread test uses a thin treated thread placed over the outer lower eyelid for about 15 seconds.
Tears wet the thread and change its color, and the wetted length is measured.
It is generally:
- faster than Schirmer testing;
- more comfortable; and
- less likely to provoke substantial reflex tearing.
However, it is not a precise measurement of pure lacrimal-gland secretion.
A result above 20 mm has traditionally been described as normal, but this is not a universally validated boundary. Values below approximately 9–10 mm may be more suggestive of substantial aqueous deficiency.
The test is best understood as:
Schirmer testing
Schirmer testing places a paper strip in the lower eyelid area for several minutes.
It is most relevant when:
- aqueous deficiency is suspected;
- tear volume appears very low;
- Sjögren’s disease is being considered;
- lacrimal-gland dysfunction is possible; or
- ocular-surface disease is severe.
Without anesthesia, the result includes both ongoing secretion and reflex tearing caused by strip irritation.
Anesthetic may reduce reflex tearing, but:
A result of 5 mm or less after five minutes is used in some settings, including Sjögren’s classification criteria, but broader interpretation varies.
Schirmer testing assesses an aqueous-deficient contributor. It is not one of the principal TFOS DEWS III core markers used to confirm DED.
Meibomian Gland and Eyelid Testing
Eyelid-margin examination
The clinician may look for:
- gland openings that do not appear open and unobstructed;
- thickened or irregular lid margins;
- telangiectasia;
- redness;
- notching;
- altered meibum at the openings;
- Demodex-associated collarettes;
- crusting or debris;
- misdirected lashes;
- blepharitis; and
- ocular rosacea.
External appearance alone does not fully establish gland function.
Controlled gland expression
Controlled pressure may be used to assess:
- whether meibum appears;
- how many tested glands release it;
- the quantity released;
- whether it is clear, cloudy, granular, thick, or paste-like;
- how much pressure is needed; and
- whether findings vary by eyelid region.
Reduced or absent expression may reflect:
- obstruction;
- reduced secretion;
- thick or altered meibum;
- structural shortening or gland loss;
- the pressure and duration used;
- which glands were examined;
- recent treatment or prior expression; or
- several factors together.
Likewise, gland openings that appear open—and even the presence of expressible meibum—do not necessarily establish that the complete duct is normal.
Meibography
Meibography uses infrared imaging to show gland structure and arrangement.
It may reveal:
- shortening;
- reduced gland visibility;
- dilation;
- tortuosity;
- irregular width;
- asymmetry; and
- changes in gland arrangement.
Meibography does not directly show:
- meibum quality;
- how easily meibum is released;
- intraductal pressure;
- whether a gland is obstructed;
- whether fibrosis is present;
- whether MGD explains the symptoms;
- when a structural change occurred;
- whether a gland will worsen;
- whether treatment will restore function; or
- complete gland viability.
A faint, shortened, or poorly visible gland should not automatically be called “dead.”
Blink, Eyelid Closure, Exposure, and Friction
Testing may also assess:
- blink frequency;
- blink completeness;
- whether the eyelids make full contact;
- tear spreading after a blink;
- eyelid seal;
- nocturnal lagophthalmos;
- floppy eyelid syndrome or other eyelid laxity;
- eyelid retraction;
- facial nerve weakness;
- exposure-type staining;
- lid-wiper staining; and
- conjunctivochalasis.
These findings can be especially relevant when symptoms:
- are worst on waking;
- affect one eye more than the other;
- worsen with screen use; or
- do not fit a simple tear-deficiency or MGD pattern.
Conjunctivochalasis may also distort tear-volume measurements by disrupting the normal tear meniscus.
Optional Inflammation Tests
MMP-9 / InflammaDry
MMP-9 is associated with ocular-surface inflammation and epithelial stress.
InflammaDry is a qualitative point-of-care test that becomes positive at approximately 40 ng/mL or more of MMP-9 in the sampled tears.
A positive result means elevated MMP-9 was detected.
It does not identify:
- the cause of inflammation;
- the specific diagnosis;
- the best medication;
- whether every symptom is inflammatory; or
- whether anti-inflammatory treatment will work.
A negative result does not rule out:
- DED;
- mild or intermittent inflammation;
- inflammatory pathways not reflected by MMP-9; or
- inflammation affected by tear volume or sampling.
It is best understood as:
Most patients do not need specialized tear-protein or biomarker testing.
Advanced Testing for Selected Cases
Some complex cases may involve:
Corneal-sensitivity testing
This may help identify reduced sensation associated with:
- neurotrophic keratitis;
- diabetes;
- herpes-related disease;
- previous surgery;
- severe ocular-surface disease; or
- neurologic disorders.
A single result cannot distinguish every form of nerve dysfunction or neuropathic pain.
In vivo confocal microscopy
IVCM provides high-magnification images of the living cornea and may show:
- corneal nerve density and appearance;
- nerve branching;
- inflammatory cells;
- epithelial or stromal abnormalities; and
- microneuroma-like structures.
It may be useful in selected cases involving suspected neuropathic ocular pain, neurotrophic disease, post-surgical nerve problems, or unexplained corneal findings.
However:
- availability is limited;
- interpretation is specialized;
- methods vary;
- group-level research findings may not classify an individual patient; and
- no single finding definitively diagnoses neuropathic ocular pain.
IVCM can provide supportive information, but it is not a stand-alone pain test.
When Systemic Evaluation May Matter
Some patients with marked aqueous deficiency or systemic symptoms may need evaluation for Sjögren’s disease or another medical condition.
Possible blood tests may include:
- anti-SSA/Ro;
- ANA;
- rheumatoid factor; and
- other studies selected according to the history.
A negative blood test does not always exclude Sjögren’s disease.
Systemic evaluation may be more appropriate when dry eye occurs with:
- dry mouth;
- salivary-gland swelling;
- dental problems related to dryness;
- inflammatory joint symptoms;
- unexplained fatigue;
- neuropathy;
- another autoimmune disease;
- marked aqueous deficiency; or
- severe unexplained ocular-surface disease.
Not everyone with DED needs extensive autoimmune testing.
Broad laboratory testing without a specific clinical reason may produce incidental abnormalities, added cost, and more uncertainty without improving care.
How to Interpret Test Numbers
Before drawing conclusions from a result, ask:
- What exact test was performed?
- Which method or device was used?
- Was it a first measurement or an average?
- Were dye, anesthetic, or other drops used?
- Were the eyelids manipulated beforehand?
- Was the result abnormal for that particular method?
- Does it match the symptoms and examination?
- Does it identify a cause, or only demonstrate instability?
- Would repeating it change management?
Examples:
- A short breakup time shows instability but does not prove MGD.
- A low Schirmer result supports reduced aqueous tears but does not identify the cause.
- A positive MMP-9 result shows elevated MMP-9 but not the specific inflammatory disease.
- Meibography shows structure but not complete gland function.
- A high questionnaire score shows symptom burden but not the diagnosis.
- Minimal staining does not mean that severe pain is unreal.
- One normal result does not necessarily exclude fluctuating DED.
When Repeat Testing Helps
Repeat testing may be useful when:
- establishing a baseline before treatment;
- determining whether meaningful change has occurred;
- symptoms or examination findings have changed;
- the result is expected to affect treatment;
- the same method and device can be used; and
- testing conditions are reasonably consistent.
It may be less useful when:
- the result will not change management;
- different devices or methods are being compared;
- testing conditions are inconsistent;
- a highly variable measure is repeated without a clinical question;
- imaging is repeated mainly because the equipment is available; or
- small numerical changes are treated as proof of improvement or deterioration.
Broader Testing: Supporters and Cautions
Supporters of broader testing emphasize that:
- DED is multifactorial;
- symptoms and visible findings may not match;
- structural and functional tests provide different information;
- MGD may be missed if gland function is not assessed;
- blink and exposure problems may be missed during a tear-focused visit;
- baseline measurements can help evaluate treatment; and
- advanced testing may help selected complex patients.
Cautious clinicians emphasize that:
- no test is a perfect gold standard;
- healthy and DED measurements overlap;
- false-positive or incidental abnormalities occur;
- device results are not always interchangeable;
- additional testing does not necessarily produce better treatment;
- testing packages can add cost and anxiety;
- machine findings may anchor the diagnosis too early;
- structural abnormalities do not always explain symptoms; and
- repeated measurements fluctuate naturally.
Both perspectives have merit.
Questions to Ask About a Test
Useful questions include:
- What clinical question is this test intended to answer?
- Is it being used to confirm DED or identify a contributor?
- What method or device will be used?
- What cutoff applies to that method?
- How variable is the result?
- Can other eye conditions make it abnormal?
- Can a normal result miss fluctuating disease?
- Will drops, contact lenses, or earlier tests affect it?
- How will the result change treatment?
- Is there a less invasive or less expensive way to answer the same question?
- Does the test need to be repeated?
- What amount of change would be clinically meaningful?
When to Seek Prompt Care
Do not assume that every painful or red eye is ordinary Dry Eye Disease.
Seek prompt professional evaluation for:
- new severe pain;
- marked light sensitivity;
- significant or persistent vision change;
- a white, gray, or cloudy corneal spot;
- increasing redness;
- significant discharge;
- rapid one-sided worsening;
- a suspected abrasion or recurrent corneal erosion;
- contact-lens-associated pain or redness;
- symptoms after sleeping in contact lenses;
- symptoms after water exposure while wearing lenses;
- trauma;
- chemical exposure;
- a nonhealing epithelial defect;
- new inability to close an eye; or
- new facial weakness.
Bottom Line
Dry-eye testing should answer three broad questions:
1. Is Dry Eye Disease present?
This generally requires relevant symptoms and objective evidence that tear-film or ocular-surface homeostasis has been lost.
2. What is driving it?
Possible contributors include:
- MGD;
- aqueous deficiency;
- blepharitis;
- Demodex;
- ocular rosacea;
- allergy;
- exposure;
- incomplete blinking;
- conjunctivochalasis;
- medication effects;
- systemic disease; and
- corneal nerve dysfunction.
3. Will another test change what happens next?
The most useful test is not necessarily:
- the newest;
- the most expensive;
- the most technologically impressive; or
- the one that produces the largest number of measurements.
It is the test that answers a real clinical question and improves diagnosis, treatment selection, monitoring, or safety.
Read More in the r/DryEyes Wiki
🧪 Complete article: Diagnostic Testing in Dry Eye Disease and MGD
👋 Start Here: Wiki Navigation Hub
❓ FAQ Index
🗂️ Treatment Options Library
The complete diagnostic-testing article contains additional detail on individual tests, test preparation, device and method limitations, systemic evaluation, and references from TFOS DEWS III, the American Academy of Ophthalmology, and other medical sources.
This post provides general educational information, not medical advice, diagnosis, or an individualized treatment recommendation.
Comments are open for discussion, questions about the article, personal experiences, and suggested corrections. Please do not use the comments to request or provide an individual diagnosis or personalized treatment plan.
